Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $25.72 in the prior trading day, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $25.5, down -0.86%. In other words, the price has decreased by -$0.86 from its previous closing price. On the day, 1.67 million shares were traded. ACAD stock price reached its highest trading level at $25.68 during the session, while it also had its lowest trading level at $25.215.
Ratios:
Our goal is to gain a better understanding of ACAD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.00. For the most recent quarter (mrq), Quick Ratio is recorded 2.83 and its Current Ratio is at 2.91. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.
Guggenheim Downgraded its Buy to Neutral on January 03, 2025, whereas the target price for the stock was revised from $23 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 02 ’25 when GAROFALO ELIZABETH A. sold 1,600 shares for $25.98 per share. The transaction valued at 41,560 led to the insider holds 25,382 shares of the business.
Schneyer Mark C. sold 22,000 shares of ACAD for $554,024 on Aug 18 ’25. The EVP, CHIEF FINANCIAL OFFICER now owns 40,130 shares after completing the transaction at $25.18 per share. On Aug 18 ’25, another insider, Schneyer Mark C., who serves as the Officer of the company, bought 22,000 shares for $25.33 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 4339283968 and an Enterprise Value of 3596459520. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.16, and their Forward P/E ratio for the next fiscal year is 31.71. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.22 while its Price-to-Book (P/B) ratio in mrq is 5.23. Its current Enterprise Value per Revenue stands at 3.53 whereas that against EBITDA is 34.593.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.79, which has changed by 0.5868077 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $26.65, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is 8.18%, while the 200-Day Moving Average is calculated to be 31.56%.
Shares Statistics:
The stock has traded on average 1.90M shares per day over the past 3-months and 2010300 shares per day over the last 10 days, according to various share statistics. A total of 168.61M shares are outstanding, with a floating share count of 167.39M. Insiders hold about 0.78% of the company’s shares, while institutions hold 101.30% stake in the company. Shares short for ACAD as of 1755216000 were 9983774 with a Short Ratio of 5.26, compared to 1752537600 on 11478190. Therefore, it implies a Short% of Shares Outstanding of 9983774 and a Short% of Float of 9.28.
Earnings Estimates
The performance of Acadia Pharmaceuticals Inc (ACAD) in the stock market is under the watchful eye of 13.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.13, with high estimates of $0.27 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.76 and $0.42 for the fiscal current year, implying an average EPS of $0.54. EPS for the following year is $0.86, with 14.0 analysts recommending between $1.93 and $0.17.
Revenue Estimates
17 analysts predict $276.52M in revenue for the current quarter. It ranges from a high estimate of $291.06M to a low estimate of $271.8M. As of the current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $250.4MFor the next quarter, 17 analysts are estimating revenue of $286.69M. There is a high estimate of $306.5M for the next quarter, whereas the lowest estimate is $278.8M.
A total of 19 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.06B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $957.8MBased on 18 analysts’ estimates, the company’s revenue will be $1.19B in the next fiscal year. The high estimate is $1.33B and the low estimate is $1.13B.
